** Sleep apnea device maker Inspire Medical Systems' shares INSP.N fall 2.9% to $175.72 in morning trade
** Co late on Monday reported Q4 adj EPS of $1.15, above Wall Street est of 73 cents - data compiled by LSEG
** INSP said they have "made steady progress" toward the full launch of sleep apnea device Inspire V during Q4
** Wells Fargo says the launch is slower than expected due to hurdles at its U.S and Mexico manufacturing plants
** Scaling up production on a new U.S. line takes time, as management aims to minimize disruption to production of the older device Inspire IV while producing Inspire V, brokerage says
** Brokerage says a civil investigation by the U.S. justice department related to allegations of false information about co's devices submitted to the agency might hurt the stock
** Brokerages Truist, Morgan Stanley and Wells Fargo cut their PTs on INSP
** Stock was down 1.3% in 2024
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。